Mehabe score: 8 G Factor: 6 Piotski Score: 9 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 6 and Piotski score of 9.
Description
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.
Main Points
Infrastructure
The company operates an established network of 216 laboratories, 3095 Patient Service Centres & ~7,000 Pick-up Units. # Out of its total labs, 33 labs are also NABL accredited. # Its flagship labs include National Reference Lab at Delhi and Regional Reference Lab at Kolkata.Site:LALPATHLABMain Symbol:LALPATHLAB
Stock trades at 3456.0, above its 50dma 3034.01. It also trades above its 200dma 2555.03. The stock remains bullish on techicals
The 52 week high is at 3497.70 and the 52week low is at 1650.25
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– has been maintaining a healthy dividend payout of 42.17%
-‘s median sales growth is 18.22% of last 10 years
Weakness
– Stock is trading at 23.14 times its book value
Competition
– The industry trades at a mean P/E of 42.4x. Max Healthcare trades at the industry’s max P/E of 546.06x. LALPATHLAB trades at a P/E of 98.5x
– Industry’s mean G-Factor is 5.0 while the mean Piotski score is 9.0. LALPATHLAB has a G-Factor of 6 and Piotski scoreof 9.
– Average 1 month return for industry is 6.7%. The max 1- month return was given by Dr Lal Pathlabs: a return of 16.44 %
Quarterly Results
Sales for period ended Mar 2021 is Rs 431.0 cr compared to Rs 302.0 cr for period ended Mar 2020, a rise of 42.7%
Operating Profits reported at Rs 122.0 cr for period ended Mar 2021 vis-vis 57.0 for period ended Mar 2020 .
Operating Margins expanded 943.2 bps for period ended Mar 2021 vis-vis Mar 2020 .
The EPS for Mar 2021 was Rs 10.01 compared to Rs 11.34 for previous quarter ended Dec 2020 and Rs 3.9 for Mar 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 1581.0 cr for period ended Mar 2021 vis-vis sales of Rs 1330.0 cr for the period ended Mar 2020, a healthy growth of 15.9%. The 3 year sales cagr stood at 14.4%.
Operating margins expanded to 28.0% for period ended Mar 2021 vis-vis 26.0% for period ended Mar 2020, expansion of 200.0 bps.
Net Profit reported at Rs 292.0 cr for period ended Mar 2021 vis-vis sales of Rs 226.0 cr for the period ended Mar 2020, rising 22.6%.
Company recorded a healthy Net Profit CAGR of 19.5% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
CashFlow from operating activities: Rs 398.0 cr for period ended Mar 2021 vis-vis Rs 284.0 cr for period ended Mar 2020
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has had stable/constant Return on Equity (RoE) metric. The RoE on Last Year basis was 25.0% compared to 23.0% over the last 3 Years. – The stock has given a return of 101% on a 1 Year basis vis-vis a return of 56% over the last 3 Years. – The compounded sales growth on a TTM bassis is 19% vis-vis a compounded sales growth of 14% over the last 3 Years. – The compounded profit growth on a TTM basis is 29% vis-vis a compounded profit growth of 20% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Mar 2021 fii holding stood at 26.01% vis-vis 24.37% for Dec 2020 – Public shareholding has remained largely constant. The Mar 2021 public holding stood at 10.37% vis-vis 10.65% for Dec 2020
Conclusion
– is almost debt free.
– has been maintaining a healthy dividend payout of 42.17%
-‘s median sales growth is 18.22% of last 10 years – Stock is trading at 23.14 times its book value
